

# CNS DISEASES

## WORLD SUMMIT 2015

Includes the co-located conferences:

**9th Neurodegenerative Conditions  
Research & Development**  
(Sept. 9-10)

**8th CNS Partnering &  
Deal-Making**  
(Sept. 10-11)

Plenary Keynote Speakers:

Jang-Ho Cha  
Vice President  
Translational Neuroscience  
Novartis

Dario Doller  
Director, Chemical Biology  
Lundbeck

Ginger Johnson  
Vice President  
Defined Health

Harry Tracy  
President  
NI Research

Gabriel Vargas  
Executive Medical Director  
Amgen

SEPTEMBER 9-11, 2015 • PHILADELPHIA, PA

**Gold Sponsor:**



**Media Partners:**

-online.com

 **pharmaceuticals**  
an open access journal by 

**GEN**  
Genetic Engineering  
& Biotechnology News

**Silver Sponsor:**

**Corporate Sponsor:**



 **Biocompare**  
The Buyer's Guide for Life Scientists

 **Taylor & Francis Group**  
an informa business


**Crossbeta**  
Biosciences



**TECHNOLOGY  
NETWORKS**

 **Current Partnering**

 **Global Information, Inc.**

  
**BENTHAM  
SCIENCE**

Visit [www.gtcbio.com](http://www.gtcbio.com) for more information!



## ABOUT

Over the past years, the field of neuroscience R&D has experienced clinical failures. The CNS Diseases World Summit seeks to find solutions by providing an interactive learning and relationship-building forum for all players in the CNS field. The program will include talks, panel discussions, and networking sessions in order to maximize attendees' dialogues and conversations. Colleagues will gather to discuss hot topics such as neuroinflammation, system biology approaches, regulatory in orphan CNS disorders, partnering with big pharma, and many more. The Summit is comprised of two back-to-back conferences:

[9th Neurodegenerative Conditions Research & Development](#) (Sept 9-10)

[8th CNS Partnering & Deal-Making](#) (Sept 10-11)

### 2014 DEMOGRAPHICS



### SPONSORSHIP OPPORTUNITIES

Our conferences are designed with our sponsors and exhibitors in mind: we create intimate and highly interactive environments so that they can maximize their reach and make long-lasting contacts. Our sponsors and exhibitors benefit from a few of the following:

- Sponsors/exhibitors have the option to receive the delegate list a week before and a week after the conference.
- The exhibit space for the meeting is shared with any other concurrent conferences, providing sponsors and exhibitors with access to a larger audience. The exhibit space is also where all networking functions take place, including coffee, snack stations, breakfast, and the evening reception.
- Your corporate logo will be placed on the cover page of the conference brochures, the proceedings given to all conference delegates, and on the presentation screen during all breaks to enhance your company's visibility at the event. Your logo will also be placed on the conference website agenda linked to your website.

*For sponsorship and exhibit opportunities, please contact:*

**Amber Kempf**

Senior Account Executive

[amber.kempf@gtcbio.com](mailto:amber.kempf@gtcbio.com)

## SPONSOR

### GOLD



**Axion BioSystems'** Maestro platform combines unparalleled microelectrode array (MEA) technology and throughput with comprehensive data analysis (AxIS) in a single easy-to-use benchtop system. Used with primary and stem cell-derived neurons, the Maestro's label-free, non-invasive, functional network activity assay offers researchers a simple approach to investigating complex neurological systems *in vitro*.

### SILVER

**Crossbeta Biosciences** develops and executes drug discovery programs for Alzheimer's and Parkinson's, ALS and Huntington's disease. Recent insight has learned that especially oligomers have detrimental effects implicated in these pathologies. Crossbeta's technology for stabilizing protein oligomers generates tools for multiple applications, such as for efficient screening of large compound libraries.



### COORPORATE



## AGENDA AT-A-GLANCE

### Day 1 - Wednesday, September 9, 2015

#### 9th Neurodegenerative Conditions Research & Development

7:00a  
7:55a

*Check In & Registration*  
*Welcome & Opening Remarks*

8:00a

Session: Hot Topics in Neurodegeneration Research: Neuroinflammation

10:05a

*Morning Networking & Coffee Break*

10:35a

Session: Advances in Parkinson's Disease Research & Therapeutics

12:20p

*Featured Lunchtime Presentation: NIH Funding*

1:30p

Session: Hot Topics in Neurodegeneration Research: Advances in Genetics and Systems Biology

3:10p

*Afternoon Networking & Coffee Break*

3:45p

Session: Biomarkers: Translation from Discovery to Clinical

5:00p

*Evening Networking Reception & Poster Session*

### Day 2 - Thursday, September 10, 2015

7:00a  
8:00a

*Registration & Continental Breakfast*  
*Welcome & Opening Remarks*

#### Joint Program

8:05a

Plenary Session: CNS: Present and Future

10:05a

*Morning Networking & Coffee Break*

10:35a

Session: Novel Therapeutics & Approaches in Alzheimer's Disease

12:15p

*Lunch on Your Own*

1:50p

Session: Novel Therapeutics & Approaches in Alzheimer's Disease (cont.)

3:05p

Panel: Is Now the Time for Neurodegeneration R&D?

3:55p

*Afternoon Networking & Coffee Break*

4:30p

Session: Rare and Orphan CNS Disorders

6:00

*Evening Networking Reception & Poster Session*

*All times are approximate and subject to changes without notice*

## AGENDA AT-A-GLANCE

Day 3 - Friday, September 11, 2015

7:00a  
7:55a

*Continental Breakfast*  
*Welcome & Opening Remarks*

8th CNS Partnering & Deal-Making

8:00a

Panel: What Sells Big Pharma in CNS?

8:40a

Panel: Partnering & Licensing Strategies in the CNS

9:20a

Session: Partnering & Licensing in CNS

10:10a

*Morning Networking & Coffee Break*

10:40a

Session: Partnering & Licensing in CNS (cont.)

11:05a

Panel: Partnering with Patient Groups to Advance Research

11:45a

Panel: Regulatory Considerations for Orphan Drug Products

12:25p

Panel: The Investor Vantage: CNS Opportunities from Perspective of Venture Capital and Public Markets

1:05p

*Lunch Provided by GTCbio*

*CNS Diseases World Summit Concludes*

*All times are approximate and subject to changes without notice*

## 9th Neurodegenerative Conditions Research & Development DISTINGUISHED SPEAKERS



*Session: Hot Topics in  
Neurodegeneration Research: Advances  
in Genetics and Systems Biology*

Alice Chen-Plotkin  
**University of Pennsylvania**




*Improving Translation Through  
Biomarker Development: Obesity Drug  
Discovery as a Case Study*

Mary Ann Pelleymounter  
**NINDS, NIH**



*System Biology Approaches to  
Understand Huntington's Disease with  
Induced Pluripotent Stem Cells*

Lisa Ellerby  
**Buck Institute for Research on Aging**



*Neuropathogenesis as a Consequence of  
Peripheral Virus Infection*

Glenn Rall  
**Fox Chase Cancer Center**




*Development and Validation of an ALS  
Diagnostic Test*

Andreas Jermomin  
**Quanterix**



*Targeting Peripheral Inflammatory Cells  
to Rescue Cognition after Traumatic  
Brain Injury*

Susanna Rosi  
**University of California, San Francisco**



*Propagation of Pathology in  
Synucleinopathies*

Kelvin Luk  
**University of Pennsylvania**



*Leveraging Genetics to Understand  
Neurodegenerative Disease*

Andrew Singleton  
**Laboratory of Neurogenetics, National  
Institute on Aging**



*Genome-Wide Transcriptional Profiles of  
Alzheimer's Disease Mouse Models and  
Comparison to Human Gene Expression*

Jacob Marcus  
**Merck**



*A Csf1r Haploinsufficient Mouse Model of  
Adult-Onset Leukodystrophy with Axonal  
Spheroids and Pigmented Glia (ALSP)*

Richard Stanley  
**Albert Einstein College of Medicine**



*Session: Biomarkers: Translation from  
Discovery to Clinical*

Ken Marek  
**Institute for Neurodegenerative  
Disorders**



*Targeting Inflammatory Pathways to  
Protect Dopaminergic Neurons in Pre-  
Clinical Models of Parkinson's Disease*

Malú Tansey  
**Emory University**



*Targeting Intrinsically Disordered  
Proteins: Taming Alpha-Synuclein with  
Small Molecules*

Lisa McConlogue  
**The University of California, San  
Francisco and The Gladstone Institute of  
Neurological Disease**



*Traumatic Brain Injury and Alzheimer's  
Disease: Progress and Perspectives*

Cheryl Wellington  
**University of British Columbia**

## JOINT PROGRAM DISTINGUISHED SPEAKERS AND PANELISTS



*Addressing Unmet Medical Needs in CNS Drug Development*

Irina Antonijevic  
**Genzyme**



*Session: Novel Therapeutics & Approaches in Alzheimer's Disease*

Cynthia McMurray  
**Solano Pharmaceuticals  
Berkeley Lab**



*Session: Novel Therapeutics & Approaches in Alzheimer's Disease*

Gai Ayalon  
**Genetech**



*Session: Novel Therapeutics & Approaches in Alzheimer's Disease*

William Mobley  
**University of California, San Diego**



*Session: Novel Therapeutics & Approaches in Alzheimer's Disease*

Robert Bell  
**Pfizer**



*Tau Based Models and Tau Approaches for the Treatment of Neurodegenerative Diseases*

Michael J. O'Neill  
**Eli Lilly**



*Targeting Regeneration of the Brain: Allopregnanolone First Regenerative Therapeutic for Alzheimer's Disease*

Roberta Brinton  
University of Southern California



*Panel: Is Now the Time for Neurodegeneration R&D?*

Bruce Rogers  
**Pfizer**



*Outcome Measures in Neuroscience Clinical Trials*

Jang-Ho Cha  
**Novartis**



*Rhes GTPase-mTORC1 Circuitry Promotes Striatal Vulnerability and Motor Dysfunction in Huntington's Disease*

Srin Subramaniam  
**The Scripps Research Institute**



*If Chemical Biology Is the Answer... What Is the Question?*

Dario Doller  
**Lundbeck**



*Is it Now Time for Neurodegeneration R&D?*

Harry Tracy  
**NI Research**



*g-Secretase Modulators for Alzheimer's Disease: Evaluation of Amyloid- $\beta$  Processing in Preclinical Animal Models*

Eva Hajos-Korcsok  
**Pfizer**



*Translational Neuroscience*

Gabriel Vargas  
**Amgen**



*Is it Now Time for Neurodegeneration R&D?*

Ginger Johnson  
**Defined Health**



*Panel: Is Now the Time for Neurodegeneration R&D?*

Ajay Verma  
**Biogen Idec**

## 8th CNS Partnering & Deal-Making DISTINGUISHED SPEAKERS AND PANELISTS



*Panel: What Sells Big Pharma in CNS*

Robert Bagdorf  
**Pfizer**



*Panel: The Investor Vantage: CNS Opportunities from Perspective of Venture Capital and Public Markets*

Kelly Lisbakken  
**Wedbush Morgan Securities**



*Panel: Regulatory Considerations for Orphan Drug Products*

Luca Benatti  
**EryDel**



*Panel: Partnering with Patient Groups to Advance Research*

Kelly Longo  
**Pfizer**



*Panel: What Sells Big Pharma in CNS*

Richard Brudnick  
**Biogen Idec**



*Panel: Regulatory Considerations for Orphan Drug Products*

Edward Mascioli  
**SV Life Sciences**



*Panel: Regulatory Considerations for Orphan Drug Products*

James Callaway  
**Armagen**



*A Partnership Focused on Aging –We Are Living Longer, but Can We Live Better?*

Joseph McCracken  
**Alkahest**



*Panel: Partnering with Patient Groups to Advance Research*

Sohini Chowdhury  
**The Michael J. Fox Foundation**



*Session: Partnering & Licensing in CNS*

Anthony McKinney  
**Neurovance**



*Panel: Regulatory Considerations for Orphan Drug Products*

Tim Cote  
**Cote Orphan Consulting**



*Panel: Partnering with Patient Groups to*

Mark Pykett  
**Agilis Biotherapeutics**



*Panel: What Sells Big Pharma in CNS*

Beth Fordham-Meier  
**NovoCreation Consulting**



*Oligomers as Target for Treatment and as Biomarker in Misfolded Protein Diseases*

Guus Scheefhals  
**Crossbeta Biosciences**

## 8th CNS Partnering & Deal-Making DISTINGUISHED SPEAKERS AND PANELISTS (cont.)



*Panel: Partnering & Licensing Strategies in the CNS*

Daniel Grau  
**Heptares Therapeutics**



*Panel: Partnering & Licensing Strategies in the CNS*

Bavani Shankar  
**AstraZeneca**



*Panel: Regulatory Considerations for Orphan Drug Products*

Marlene Haffner  
**Haffner Associates**



*Leveraging Genetics to Understand Neurodegenerative Disease*

Andrew Singleton  
**NIA, National Institutes of Health**



*Panel: Partnering with Patient Groups to Advance Research*

Jeff Karan  
**Mavericks Capital**



*Panel: What Sells Big Pharma in CNS*

John Renger  
**Merck**



*Panel: The Investor Vantage: CNS Opportunities from Perspective of Venture Capital and Public Markets*

Bruce Leuchter  
**Credit Suisse**



*Panel: What Sells Big Pharma in CNS*

Ryan Westphal  
**Eli Lilly**

## CONFERENCE DETAILS

### REGISTRATION

#### Early Registration Discount:

20% until July 9, 2015

10% until August 9, 2015

Register for 2 the 3rd goes FREE with coupon code: **RCDVB**

To register online, visit: [www.gtcbio.com/register/cns-diseases-world-summit](http://www.gtcbio.com/register/cns-diseases-world-summit)

|                       | Commercial | Academic / Govt | Student |
|-----------------------|------------|-----------------|---------|
| CNS Summit            | 1995.00    | 1045.00         | 895.00  |
| Individual Conference | 1795.00    | 845.00          | 695.00  |

### CALL FOR PAPERS

GTCbio encourages attendees to gain exposure by presenting their work in the poster sessions. Your research will be seen by leaders from top pharmaceutical, biotech, academic and government institutions, and will also be published in the conference materials. The top 2-3 qualified submitted abstracts will also be selected by the meeting's scientific advisory board for the chance to give a short oral presentation in the conference program. To be considered for a short oral presentation, please submit an abstract by **August 9, 2015**. Selected presentations will be based on quality of abstract and availability. Selected abstracts will be notified via email or telephone 2-3 weeks before the conference. Presentation slots fill up fast so please submit your abstract soon. Click on the following conferences to submit an abstract:

[9th Neurodegenerative Conditions Research & Development](#)

[8th CNS Partnering & Deal-Making](#)

### VENUE

#### Loews Philadelphia Hotel

1200 Market St  
Philadelphia, PA 19107  
(215) 627-1200

**Discounted Group Rate: \$169.00 per night**

**Discount Deadline: August 10, 2015**

Toll Free Reservations: 1-888-575-6397

*Mention GTCbio to receive the group rate.*



Online Reservations:

[https://resweb.passkey.com/Resweb.do?mode=welcome\\_ei\\_new&eventID=13876392](https://resweb.passkey.com/Resweb.do?mode=welcome_ei_new&eventID=13876392)

### PROCEEDINGS

If you are unable to attend the conference you can purchase the proceedings by downloading the order form [here](#). Fill out the order form and fax it to 1 (626) 433-4433 or email it to [proceedings@gtcbio.com](mailto:proceedings@gtcbio.com).